BACKGROUND: Most alcoholics experience periods of voluntary alcohol abstinence or imposed alcohol deprivation followed by a return to alcohol drinking. This study examined whether varenicline (VAR) reduces alcohol intake during a return to drinking after periods of alcohol deprivation in rats selectively bred for high alcohol drinking (the alcohol preferring or "P" rats). METHODS: Alcohol-experienced P rats were given 24-hour access to food and water and scheduled access to alcohol (15% and 30% v/v) for 2 h/d. After 4 weeks, rats were deprived of alcohol for 2 weeks, followed by reaccess to alcohol for 2 weeks, and this pattern was repeated for a total of 3 cycles. Rats were fed either vehicle (VEH) or VAR, in doses of 0.5, 1.0, or 2.0 mg/kg BW, at 1 hour prior to onset of the daily alcohol reaccess period for the first 5 days of each of the 3 alcohol reaccess cycles. RESULTS: Low-dose VAR (0.5 mg/kg BW) reduced alcohol intake during the 5 days of drug treatment in alcohol reaccess cycles 1 and 2. Higher doses of VAR (1.0 mg/kg BW and 2.0 mg/kg BW) reduced alcohol intake during the 5 days of treatment in all 3 alcohol reaccess cycles. The decrease in alcohol intake disappeared with termination of VAR treatment in all alcohol reaccess cycles. CONCLUSIONS: The results demonstrate that VAR decreases alcohol intake during multiple cycles of alcohol reaccess following alcohol deprivation in rats and suggests that it may prevent a return to heavy alcohol drinking during a lapse from alcohol abstinence in humans with alcohol use disorder.
BACKGROUND: Most alcoholics experience periods of voluntary alcohol abstinence or imposed alcohol deprivation followed by a return to alcohol drinking. This study examined whether varenicline (VAR) reduces alcohol intake during a return to drinking after periods of alcohol deprivation in rats selectively bred for high alcohol drinking (the alcohol preferring or "P" rats). METHODS:Alcohol-experienced P rats were given 24-hour access to food and water and scheduled access to alcohol (15% and 30% v/v) for 2 h/d. After 4 weeks, rats were deprived of alcohol for 2 weeks, followed by reaccess to alcohol for 2 weeks, and this pattern was repeated for a total of 3 cycles. Rats were fed either vehicle (VEH) or VAR, in doses of 0.5, 1.0, or 2.0 mg/kg BW, at 1 hour prior to onset of the daily alcohol reaccess period for the first 5 days of each of the 3 alcohol reaccess cycles. RESULTS: Low-dose VAR (0.5 mg/kg BW) reduced alcohol intake during the 5 days of drug treatment in alcohol reaccess cycles 1 and 2. Higher doses of VAR (1.0 mg/kg BW and 2.0 mg/kg BW) reduced alcohol intake during the 5 days of treatment in all 3 alcohol reaccess cycles. The decrease in alcohol intake disappeared with termination of VAR treatment in all alcohol reaccess cycles. CONCLUSIONS: The results demonstrate that VAR decreases alcohol intake during multiple cycles of alcohol reaccess following alcohol deprivation in rats and suggests that it may prevent a return to heavy alcohol drinking during a lapse from alcohol abstinence in humans with alcohol use disorder.
Authors: Susmita Chatterjee; Pia Steensland; Jeffrey A Simms; Joan Holgate; Jotham W Coe; Raymond S Hurst; Christopher L Shaffer; John Lowe; Hans Rollema; Selena E Bartlett Journal: Neuropsychopharmacology Date: 2010-11-03 Impact factor: 7.853
Authors: Janice C Froehlich; Brett Hausauer; Stephen Fischer; Bradley Wise; Dennis D Rasmussen Journal: Alcohol Clin Exp Res Date: 2015-08 Impact factor: 3.455
Authors: Stephen A Maisto; Corey R Roos; Kevin A Hallgren; Dezarie Moskal; Adam D Wilson; Katie Witkiewitz Journal: Alcohol Clin Exp Res Date: 2016-09-03 Impact factor: 3.455
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams Journal: Neuropharmacology Date: 2006-12-08 Impact factor: 5.250
Authors: John A Stapleton; Lucy Watson; Lucy I Spirling; Robert Smith; Andrea Milbrandt; Marina Ratcliffe; Gay Sutherland Journal: Addiction Date: 2007-11-19 Impact factor: 6.526
Authors: Joseph P Schacht; Raymond F Anton; Patrick K Randall; Xingbao Li; Scott Henderson; Hugh Myrick Journal: Psychopharmacology (Berl) Date: 2014-03-20 Impact factor: 4.530
Authors: Kim Donoghue; Catherine Elzerbi; Rob Saunders; Craig Whittington; Stephen Pilling; Colin Drummond Journal: Addiction Date: 2015-03-17 Impact factor: 6.526
Authors: Robert A Waeiss; Christopher P Knight; Sheketha R Hauser; Lauren A Pratt; William J McBride; Zachary A Rodd Journal: Psychopharmacology (Berl) Date: 2019-02-13 Impact factor: 4.530
Authors: Sarah E Maggio; Meredith A Saunders; Thomas A Baxter; Kimberly Nixon; Mark A Prendergast; Guangrong Zheng; Peter Crooks; Linda P Dwoskin; Rachel D Slack; Amy H Newman; Richard L Bell; Michael T Bardo Journal: Psychopharmacology (Berl) Date: 2018-02-18 Impact factor: 4.530
Authors: Sarah E Maggio; Meredith A Saunders; Kimberly Nixon; Mark A Prendergast; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Richard L Bell; Michael T Bardo Journal: Drug Alcohol Depend Date: 2018-10-17 Impact factor: 4.492